Mechanism of Neostigmine Side Effects
Neostigmine is widely used to reverse non-depolarizing neuromuscular blockade and to treat conditions such as myasthenia gravis. The therapeutic and side effects of neostigmine arise from the same fundamental action: increasing the concentration of acetylcholine at synapses. Because acetylcholine acts on both muscarinic and nicotinic receptors throughout the body, any excessive accumulation produces predictable physiological responses ¹⁻².
Neostigmine’s primary mechanism is to inhibit acetylcholinesterase, the enzyme that normally breaks down acetylcholine. When this enzyme is blocked, acetylcholine accumulates at neuromuscular junctions and parasympathetic synapses. While this enhances the ability of skeletal muscles to contract, it also leads to widespread cholinergic stimulation. The excessive signaling created by this buildup forms the basis of most neostigmine-related side effects ³⁻⁴.
A large proportion of neostigmine’s adverse effects come from heightened muscarinic activity. Increased acetylcholine enhances vagal tone in the heart, which can slow heart rate and reduce conduction through the atrioventricular node. This bradycardia is a well-recognized risk, which is why neostigmine is usually given together with an antimuscarinic agent such as glycopyrrolate or atropine.
In the respiratory and gastrointestinal systems, overstimulation of muscarinic receptors increases secretions and smooth-muscle contraction. Patients may experience increased salivation, excess bronchial mucus, wheezing, or bronchoconstriction. In addition, enhanced gut motility can lead to abdominal cramping, nausea, or diarrhea. These effects reflect the global activation of the parasympathetic system ⁵⁻⁶.
Neostigmine also increases acetylcholine at nicotinic receptors located at skeletal neuromuscular junctions. At therapeutic levels, this increases muscle strength, but excessive stimulation can have the opposite effect. An initial phase of muscle twitching or fasciculation may occur, followed by weakness if the receptors become overstimulated and less responsive. This paradox, facilitating neuromuscular transmission while simultaneously risking fatigue, explains some of the transient motor symptoms observed after administration ⁴⁻⁷.
Since neostigmine is a quaternary ammonium compound, it does not easily cross the blood–brain barrier. As a result, central nervous system side effects are generally limited and uncommon ².
Neostigmine’s enhancement of parasympathetic activity without a corresponding increase in sympathetic tone can create a temporary autonomic imbalance. This may manifest as sweating, miosis, or fluctuations in blood pressure. These effects are usually mild and short-lived but illustrate the broad physiological impact of cholinesterase inhibition ⁸⁻¹⁰.
The side effects of neostigmine are best understood as the natural consequence of excessive cholinergic stimulation. By inhibiting acetylcholinesterase, neostigmine increases acetylcholine levels not only where it is needed but also in tissues where surplus activity causes unwanted effects. Understanding these mechanisms allows clinicians to anticipate adverse reactions, administer protective agents such as antimuscarinic agents and use the medication safely and effectively.
References
1. Neostigmine (injection route) – Side effects & uses. Mayo Clinic https://www.mayoclinic.org/drugs-supplements/neostigmine-injection-route/description/drg-20071686.
2. Neely, G. A., Sabir, S. & Kohli, A. Neostigmine. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2025).
3. Cholinergic Stimulation – an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/cholinergic-stimulation.
4. Si, S. et al. New advances in clinical application of neostigmine: no longer focusing solely on increasing skeletal muscle strength. Front. Pharmacol. 14, (2023). DOI: 10.3389/fphar.2023.1227496
5. Neostigmine. https://go.drugbank.com/drugs/DB01400.
6. Kudlak, M. & Tadi, P. Physiology, Muscarinic Receptor. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2025).
7. Adeyinka, A., Patel, A. & Kondamudi, N. P. Cholinergic Crisis. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2025).
8. Neostigmine – an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/neuroscience/neostigmine.
9. Wells, R. & Tonkin, A. Clinical approach to autonomic dysfunction. Internal Medicine Journal 46, 1134–1139 (2016). DOI: 10.1111/imj.13216
10. Chamma, A. G. et al. Neostigmine-Atropine Combination Triggered Stress Cardiomyopathy in a Healthy Patient: A Case Report and Literature Review. Cureus 17, (2025). DOI: 10.7759/cureus.91738